Global First-in-Human (FIH) Services Market Growth (Status and Outlook) 2025-2031

The global First-in-Human (FIH) Services market size is predicted to grow from US$ 667 million in 2025 to US$ 1299 million in 2031; it is expected to grow at a CAGR of 11.7% from 2025 to 2031.

First-in-Human Services refer to specialized services that support the planning, execution, and management of First-in-Human (FIH) clinical trials. These services are critical for the successful transition of a drug or therapeutic product from preclinical development to initial testing in human subjects. FIH trials are typically the first time a new drug is administered to humans, making the associated services essential for ensuring safety, compliance, and scientific validity.First-in-Human Services are essential for minimizing risks associated with the early testing of new drugs in humans, ensuring regulatory compliance, and generating reliable data that can influence subsequent phases of drug development. These services help streamline the clinical trial process, improve efficiency, and enhance the likelihood of successful product development.

United States market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for First-in-Human (FIH) Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key First-in-Human (FIH) Services players cover WuXi AppTec, Allucent, Altasciences, LAXAI, Lonza, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “First-in-Human (FIH) Services Industry Forecast” looks at past sales and reviews total world First-in-Human (FIH) Services sales in 2024, providing a comprehensive analysis by region and market sector of projected First-in-Human (FIH) Services sales for 2025 through 2031. With First-in-Human (FIH) Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world First-in-Human (FIH) Services industry.

This Insight Report provides a comprehensive analysis of the global First-in-Human (FIH) Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on First-in-Human (FIH) Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global First-in-Human (FIH) Services market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for First-in-Human (FIH) Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global First-in-Human (FIH) Services.

This report presents a comprehensive overview, market shares, and growth opportunities of First-in-Human (FIH) Services market by product type, application, key players and key regions and countries.

Segmentation by Type:
Drugs
Medical Device

Segmentation by Application:
Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic Institutions and Research Centers
Medical Device Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi AppTec
Allucent
Altasciences
LAXAI
Lonza
Syneos Health
CD BioSciences
Fortrea
Certara
Evotec
Aixial Group
Quotient Sciences
Sofpromed
Spaulding Clinical
Biotrial
Crystal Pharmatech Co., Ltd
Avania

Please note: The report will take approximately 2 business days to prepare and deliver.